Celldex Therapeutics, Inc.(NASDAQ:CLDX) Reports Results

0
531

Dallas, Texas 02/19/2014 (FINANCIALSTRENDS) – Celldex Therapeutics, Inc.(NASDAQ:CLDX) is the MA based biopharmaceutical company which  builds therapies for such diseases as those which do not have a cure yet. Major products for this company are in the category of cancer drugs. The company specializes in building drugs which are immunotherapy technologies which are very popular to treat cancer.

Celldex Therapeutics, Inc.(NASDAQ:CLDX) drug candidates are the CDX-110 as well as the CDX-1127.

CDX-110, is the immunotherapeutic vaccine is expected to stop the growth of the specific molecule which causes the tumor to grow. The concern here is the epidermal growth where are the receptor variant III. CDX27 is also called the co-stimulatory molecule with respect to T cells, when the condition develops when the lymphomas as well as the leukaemias are overly expressed.

Celldex Therapeutics, Inc.(NASDAQ:CLDX) also has the CDX-1401 which is especially popular for its APC Targeting technology programs. Moreover, the CDX-301, is also the immune cell mobilizing agent. The high cell growth factor along with dendritic growth, followed by CDX-1135 which works as a molecule to inhibit the immune system are also called as the complement systems. The company has been working on the CDX-301 and the Mozobil combination. The results of the preclinical study have revealed that the agents have shown a related rise in the stem cell mobilization for mice as well as the future clinical development of CDX-301, besides demonstrating a novelty feature.

The concept is to do with mobilization of the regimen.

Celldex Therapeutics, Inc.(NASDAQ:CLDX) had in the month of December offered a discount on its public offerin, showing a sharp lowering in the region of $24.50, close to 6.4% discount over regular price. The net proceeds during the month was $162.725 million.

For Celldex Therapeutics, Inc.(NASDAQ:CLDX), the downward slide was first noticed following the interim data report for its candidate ReACT. The results were to ‘demonstrate clinical activity’ in the brain cancer patients.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.